FDA Warning Letter criticizes Supplier Qualification
Recommendation
Tuesday, 24 February 2026 13.00 - 16.30 h
Compliant and Successful Self-Inspections and Internal Audits
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
CMO Supplier Qualification and the respective contracts in outsourcing activities are always hot topics in inspections. The U.S. Food and Drug Administration (FDA) recently posted a Warning Letter sent to a pharmaceutical company in the US criticizing their supplier qualification and oversight. The inspection was scheduled because of problems at the company's CMO.
For example, the company "failed to have adequate supplier qualification procedures to ensure that the drug products received" from CMOs "were manufactured in compliance with CGMP." They also "failed to have adequate procedures" to ensure tht all drug products produced for the firm met "appropriate quality attributes".
The company now has to evaluate the supplier and CMO qualification program, "including a plan to conduct periodic audits". In the Warning Letter, the FDA clearly points out that the company is responsible for the quality of the drugs "regardless of agreements in place" with CMOs.
Related GMP News
03.12.2025What are GMP Audits and what Qualifications do GMP Auditors need to have?
19.11.2025Root Cause Analysis and CAPA - Why FDA Keeps Calling Them Out
22.10.2025EMA Questions & Answers on Mutual Recognition Agreement (MRA) with US updated
22.10.2025FDA continues to take Root Cause Analysis and CAPA very seriously